The hardware and bandwidth for this mirror is donated by dogado GmbH, the Webhosting and Full Service-Cloud Provider. Check out our Wordpress Tutorial.
If you wish to report a bug, or if you are interested in having us mirror your free-software or open-source project, please feel free to contact us at mirror[@]dogado.de.
A Budget Impact Analysis (BIA) estimates the financial consequences of adopting a new health technology from the payer’s perspective over a short time horizon (typically 1-5 years). Unlike cost-effectiveness analysis, BIA focuses on affordability, not value for money. ParCC implements the ISPOR BIA Good Practice framework.
You are advising a state health insurance programme on adopting a new oral anticoagulant (NOAC) to replace warfarin for Atrial Fibrillation.
| Parameter | Value |
|---|---|
| Covered population | 10,000,000 enrolees |
| AF prevalence | 0.8% (80,000 patients) |
| Eligible for anticoagulation | 60% of AF patients (48,000) |
| Uptake trajectory | Yr 1: 10%, Yr 2: 25%, Yr 3: 45%, Yr 4: 60%, Yr 5: 70% |
| Current therapy (warfarin) | INR 8,000/patient/year (drug + INR monitoring) |
| New therapy (NOAC) | INR 22,000/patient/year (drug only) |
| Discount rate | 3% per year |
The BIA compares two scenarios:
\[BI_t = N_{target} \times Uptake_t \times (C_{new} - C_{current}) \times \frac{1}{(1+r)^{t-1}}\]
ParCC produces:
ISPOR recommends 1-5 years, matching the payer’s budget cycle. Longer horizons introduce too much uncertainty in uptake projections.
Real-world adoption follows an S-curve, not instant switching. Conservative estimates in early years are more credible. ParCC allows independent specification for each year.
The primary BIA should be undiscounted (set rate to 0%) since payers care about actual cash flows. Discounted results can be presented as a secondary analysis for consistency with CEA.
ParCC uses a static population (same eligible count each year). For diseases with significant incidence/mortality, a dynamic population model may be needed – this is beyond ParCC’s current scope.
The ISPOR 2012 Task Force recommends:
These binaries (installable software) and packages are in development.
They may not be fully stable and should be used with caution. We make no claims about them.
Health stats visible at Monitor.